Prognostic and immunotherapeutic significance of ARV1 in colorectal cancer
10.3760/cma.j.cn431274-20240315-00430
- VernacularTitle:ARV1在结直肠癌患者预后及免疫治疗中的意义
- Author:
Zizhu LIU
1
;
Zhicong XIAO
;
Chunsheng LIU
;
Ping WANG
;
Yue ZHANG
;
Xueqing YAO
Author Information
1. 华南理工大学医学院，广州 510006
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
ARV1;
Immunotherapy;
Immune infiltration
- From:
Journal of Chinese Physician
2025;27(9):1318-1324
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the prognostic and immunotherapeutic significance of androgen receptor V1 (ARV1) in colorectal cancer (CRC) and to explore its mechanism in CRC progression.Methods:The relationship between ARV1 expression and CRC prognosis was analyzed using data from The Cancer Genome Atlas Program (TCGA). Gene ontology (GO) analysis was performed to identify potential mechanisms through which ARV1 regulates CRC progression. Multiple public databases were used to analyze the correlation between ARV1 and immune cell infiltration and to predict the sensitivity of ARV1 to immunotherapy and chemotherapeutic drugs. Immunohistochemical validation was conducted using postoperative specimens from 199 CRC patients, and clinical correlations were analyzed.Results:ARV1 expression was significantly lower in CRC tissues compared to normal tissues ( P<0.001). Patients with high ARV1 expression exhibited better overall survival than those with low expression ( P=0.016). Clinical analysis indicated that ARV1 serves as an independent prognostic factor in CRC, and its expression was associated with age and clinical stage (all P<0.01). GO analysis revealed that ARV1 influenced multiple pathways in CRC. Immune-related analysis demonstrated that ARV1 participated in regulating immune cell infiltration in CRC. Drug sensitivity analysis showed differences in responses to various chemotherapeutic agents between high and low ARV1 expression groups ( P<0.01). In immunotherapy, significant differences in Immunophenotype Score (IPS) were observed between high and low ARV1 expression groups in PD1-negative/CTLA4-negative patients ( P<0.05). Immunohistochemical results from 199 CRC patients confirmed that low ARV1 expression was associated with poorer prognosis ( P<0.001). Conclusions:ARV1 expression affects CRC prognosis and may serve as a potential novel biomarker for immunotherapy in CRC.
